{"id":728216,"date":"2023-02-02T08:40:22","date_gmt":"2023-02-02T13:40:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-02T08:40:22","modified_gmt":"2023-02-02T13:40:22","slug":"compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/","title":{"rendered":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON, Feb.  02, 2023  (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 \u2013 16, 2023.<\/p>\n<p align=\"justify\">\n        <strong>Fireside Chat details: <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Date: <\/strong>Wednesday, February 15<br \/><strong>Time: <\/strong>11:20 AM ET <br \/><strong>Webcast: <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1ohzmxwsiks9DEtGITHSIqMtIWR7SfGQiF2RrrdQDvjnRcIMAMTt_j1O1E8gilPcHBL8W6B73wH8CD_PFAS7BvG-wCksQ2xtdi49JsYXScEyMK9X3OUjWI1nXcvk-MllVr4-QcIhj0z1x5d-9cFgcQ==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/wsw.com\/webcast\/svb8\/cmpx\/1631304<\/a><\/p>\n<p>\n        <strong>Virtual\/Replay availability: <\/strong>The corporate presentation will be archived for 90 days on Compass\u2019 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mHyCVgn9zzT5o8pubVHovXn7-h7sCIYhSgbI_IN7iRXHkZB3aiK9LrUlPqI5CrS9uRwsE3uYBZDjieMdm_tvCV4Jdzs73cKeoRTLzWSDhrNb2nY1DvYRA0v75p7xVKPT\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a> page.<\/p>\n<p>\n        <strong>About Compass Therapeutics<\/strong>\n      <\/p>\n<p>Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass\u2019s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7cJ-i8lD52rwYmIAL8Zaj-g9dWkhtfpAxK8_MBNxmxit5BadiuIckwEJFkav9MsxAaD_2Yxml4IYBdv9AMUkzwR1i9gPPLgKLF62mb8A5oazio0aCzDRveooasRqkb73\" rel=\"nofollow noopener\" target=\"_blank\">www.compasstherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Mario Corso, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k4JfqSHnBhtFFeRNNl-NTQKU7w9Nk4Z4y8ZxVBg8HrTqQJTg-fwpbEnki6eGZWZiYdbmrWSmUli_bZEo7AjwWdDop6Whk06GSgtawX1Ky0c9c5oVgXHjr4QxoDg4Tof7\" rel=\"nofollow noopener\" target=\"_blank\">ir@compasstherapeutics.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Anna Gifford, Communications Manager<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Prhb9u6uILiRdm3sFQ3Tfgl7so2xR4nwaQ1ffRbxxGxYwkVxlpb4896MjrGpW_qN_VxiofdA29rfxYpK2MB4FDIE9YoeIFKoXJ_WEx0S_YrBRdRqpVBUTtAFlxTXP8bL\" rel=\"nofollow noopener\" target=\"_blank\">media@compasstherapeutics.com<\/a><br \/>617-500-8099<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmQyMzUxNzgtYzc4MS00MGMxLWJmYmMtMmU4ODY0YWMwMWQ4LTEyMTM5NzU=\/tiny\/Compass-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 \u2013 16, 2023. Fireside Chat details: Date: Wednesday, February 15Time: 11:20 AM ET Webcast: https:\/\/wsw.com\/webcast\/svb8\/cmpx\/1631304 Virtual\/Replay availability: The corporate presentation will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass\u2019s pipeline of novel product candidates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728216","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 \u2013 16, 2023. Fireside Chat details: Date: Wednesday, February 15Time: 11:20 AM ET Webcast: https:\/\/wsw.com\/webcast\/svb8\/cmpx\/1631304 Virtual\/Replay availability: The corporate presentation will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass\u2019s pipeline of novel product candidates &hellip; Continue reading &quot;Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T13:40:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-02T13:40:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":252,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\",\"datePublished\":\"2023-02-02T13:40:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 \u2013 16, 2023. Fireside Chat details: Date: Wednesday, February 15Time: 11:20 AM ET Webcast: https:\/\/wsw.com\/webcast\/svb8\/cmpx\/1631304 Virtual\/Replay availability: The corporate presentation will be archived for 90 days on Compass\u2019 Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass\u2019s pipeline of novel product candidates &hellip; Continue reading \"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-02T13:40:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference","datePublished":"2023-02-02T13:40:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/"},"wordCount":252,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/","name":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=","datePublished":"2023-02-02T13:40:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MTI2MCM1Mzg3NTA4IzIyMDI0MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728216"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}